| Name | Title | Contact Details |
|---|---|---|
Philip Johnson |
Vice President Science, Clinical, and R&D | Profile |
Ryan Kaveckis |
Director of Research and Development | Profile |
HOT CELL SERVICES CORPORATION is a Kent, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Xenter, Inc. is a privately held company headquartered in Salt Lake City, Utah, that is focused on developing new wireless medical device technologies, innovative digital health tools that will enable individual patients to own and manage their health information, and novel therapeutic drugs utilizing Physical Intelligence™ and patient-supplied data. Xenter has assembled a team of medical scientists, chemical engineers, medical device engineers, researchers, data scientists, and some of the world`s most accomplished entrepreneurs and industry veterans to solve some of the largest challenges in healthcare, medicine and engineering.
Advanced Micronic Devices is a Cerritos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lab Vision Corporation is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Silk Road Medical, Inc. is a medical device company located in Sunnyvale, California, that is focused on reducing the risk of stroke and its devastating impact. The company has pioneered a new approach for the treatment of carotid artery disease called TransCarotid Artery Revascularization (TCAR). TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. The TransCarotid Artery Revascularization (TCAR) Procedure is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. The ENROUTE® Transcarotid Neuroprotection and Stent System are the first and only products specifically designed and indicated for TCAR in high surgical risk patients that need carotid intervention.